Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200 Day Moving Average – Time to Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $10.65 and traded as low as $6.42. Karyopharm Therapeutics shares last traded at $6.51, with a volume of 45,358 shares traded.

Analysts Set New Price Targets

Several analysts have commented on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. HC Wainwright upped their price target on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. Finally, Robert W. Baird cut their price target on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Karyopharm Therapeutics Stock Down 13.4 %

The stock has a market capitalization of $40.82 million, a PE ratio of -4.75 and a beta of 0.11. The firm’s fifty day moving average price is $8.41 and its two-hundred day moving average price is $10.57.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million for the quarter, compared to analysts’ expectations of $30.29 million. As a group, analysts predict that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Velan Capital Investment Management LP purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter worth $27,000. Focus Partners Wealth bought a new stake in Karyopharm Therapeutics in the 4th quarter valued at $31,000. TD Waterhouse Canada Inc. purchased a new stake in Karyopharm Therapeutics in the 4th quarter worth $32,000. Two Sigma Advisers LP grew its position in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares in the last quarter. Finally, Opti Capital Management LP bought a new stake in Karyopharm Therapeutics in the fourth quarter worth $85,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).